We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-1.46 | -1.50% | 95.81 | 97.83 | 97.11 | 97.63 | 1,180,808 | 01:00:00 |
By Kim Richters
Swiss pharmaceuticals company Novartis AG (NOVN.EB) on Thursday raised its full-year sales and core operating income guidance, saying it saw strong sales in the second quarter.
Novartis now expects its 2019 core operating income to grow low double-digit to mid-teens and net sales to grow mid to high-single digits. The revised guidance assumes that no Gilenya generics will enter the U.S. in 2019.
Net profit attributable to shareholders fell to $6.8 billion from $7.77 billion the same period last year and net income from continuing operations excluding Alcon, which went public in April, declined to $2.11 billion from $7.73 billion after a nearly $6 billion one-off gain from the sale of Novartis's stake in its joint consumer health-care venture with GlaxoSmithKline PLC (GSK.LN).
Core operating profit, a figure watched by analysts that strips out extraordinary items, grew to $3.65 billion from $3.21 billion. Net sales grew to $11.76 billion from $11.34 billion, mainly due to strong sales of the company's Cosentyx and Entresto drugs, according to Novartis.
"Novartis delivered an exceptional first-half performance in 2019 as a focused medicines company with strong sales and productivity driving double-digit core operating income growth with margin expansion," Novartis Chief Executive Vas Narasimhan said.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
July 18, 2019 01:59 ET (05:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions